CVS Health reported earnings that beat analysts’ expectations and kept its 2026 profit guidance unchanged, results that may soothe investors spooked by continued turmoil in the health-insurance sector https://t.co/hRH025uZH8 ...

Core Insights - Encompass Health (EHC) is positioned as a sustainable growth story within the healthcare services sector, contrasting with other segments that are influenced by speculative disruption and unpredictable reimbursement dynamics [1] Company Overview - Encompass Health is the largest provider in its field, indicating a strong market presence and potential for continued growth [1]

Core Insights - CVS Health Corporation reported fourth-quarter 2025 adjusted earnings per share (EPS) of $1.09, an 8.4% decline year over year, but exceeded the Zacks Consensus Estimate by 10.1% [1][9] - The company's total revenues for the fourth quarter rose 8.2% year over year to $105.69 billion, surpassing the Zacks Consensus Estimate by 2.2% [3][9] - CVS Health's full-year adjusted EPS was $6.75, a 24.5% increase from 2024, beating the Zacks Consensus Estimate by 1.5% [2] Revenue Performance - Health Services revenues increased 9% year over year to $51.24 billion, driven by pharmacy drug mix and brand inflation, despite a 7.5% decline in total pharmacy claims processed [4] - Revenues in the Pharmacy & Consumer Wellness segment rose 12.4% year over year to $37.66 billion, primarily due to increased prescription volume and acquisitions, offset by reimbursement pressure [5] - The Health Care Benefits segment reported revenues of $36.29 billion, up 10.1% year over year, largely due to the Government business and the Inflation Reduction Act's impact on Medicare Part D [6] Margin Analysis - The combined cost of products sold and healthcare costs rose 8.6% to $92.13 billion, while gross profit increased 5.2% to $13.57 billion, leading to a gross margin contraction of 37 basis points to 12.8% [7] - Adjusted operating margin contracted 44 basis points to 1.9%, despite an 8.9% rise in total operating expenses to $11.46 billion [7] Liquidity Position - CVS Health ended 2025 with cash and cash equivalents of $8.45 billion, a slight decrease from $8.59 billion at the end of 2024, while long-term debt increased to $64.57 billion from $64.15 billion [8] Future Guidance - CVS Health provided 2026 adjusted EPS guidance in the range of $7.00-$7.20, with the Zacks Consensus Estimate currently at $7.15 [11] Overall Assessment - CVS Health's fourth-quarter earnings and revenues exceeded estimates, with year-over-year revenue growth across all segments. However, higher costs and expenses led to margin contraction and bottom-line pressure [12]

Core Insights - Centene Corporation (NYSE:CNC) is recognized as a promising healthcare stock priced under $50, with Morgan Stanley maintaining a Hold rating and a price target of $38.00 [1][2] Financial Performance - For the full year 2025, Centene reported a GAAP diluted loss per share of $13.53 and an adjusted diluted Earnings Per Share (EPS) of $2.08 [2] - The consolidated Health Benefits Ratio (HBR) for fiscal Q4 2025 was 94.3%, with a Commercial HBR of 95.4%, exceeding expectations by 100 basis points, attributed to net out-of-period items [2] - The Medicaid HBR for the quarter was 93.0%, showing a sequential improvement of 40 basis points compared to Q3 [2] Future Outlook - Centene anticipates renewed adjusted diluted EPS growth and significant margin improvement in 2026, projecting full-year adjusted diluted EPS to exceed $3.00 [3] - This projection indicates a substantial recovery in the company's embedded earnings power [3] Company Overview - Centene Corporation operates as a healthcare enterprise providing services to government-sponsored healthcare programs, with segments including Medicaid, Medicare, Commercial, and Other [4]

CVS Health reported earnings that beat analysts’ expectations and kept its 2026 profit guidance unchanged, results that may soothe investors spooked by continued turmoil in the health-insurance sector. https://t.co/Q6CYRQ7Uhb ...

Core Insights - The Q4 earnings season for 2025 has been positive, with strong growth and many companies exceeding expectations, except for NVIDIA [1] Boot Barn (BOOT) - Boot Barn reported a 16% year-over-year increase in sales, with same-store sales rising by 5.7%, indicating strong performance in existing stores while expanding [2][4] - The company opened 25 new locations, bringing the total to 514, and achieved a gross margin of 39.9%, up from 39.3% year-over-year, reflecting improved profitability [4][6] - Boot Barn anticipates opening 70 new stores in FY26, with projected sales between $2.24 billion and $2.25 billion, and same-store sales growth expected to be between 6.5% and 7.5% [8] Cardinal Health (CAH) - Cardinal Health experienced an 18.8% year-over-year sales increase and a 36.3% growth in adjusted EPS, marking a significant recovery after stagnation in 2024 [9][12] - Sales growth was broad-based, with Pharmaceuticals and Specialty Solutions up 19% year-over-year, contributing approximately 90% of total sales [12] - The company raised its FY26 outlook for adjusted EPS to a range of $10.15 to $10.35, suggesting a 24.5% year-over-year growth [14] Overall Market Sentiment - Both Boot Barn and Cardinal Health have raised their guidance following strong quarterly results, indicating potential near-term outperformance [16]

A live audio webcast of the presentation will be accessible through Johnson & Johnson's Investor Relations website at www.investor.jnj.com. An archived edition of the session will be available later that day. The audio webcast replay will be available approximately 48 hours after the webcast. thth NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will present at the Barclays 28 Annual Global Healthcare Conference on Tuesday, March 10, 2026. Management will participate in a Fireside Chat at ...

Core Insights - Encompass Health Corporation (EHC) reported fourth-quarter 2025 adjusted earnings per share (EPS) of $1.46, exceeding the Zacks Consensus Estimate by 13.2% and reflecting a year-over-year increase of 24.8% [1][9] - The company's net operating revenues reached $1.5 billion, marking a 9.9% year-over-year improvement and slightly surpassing the consensus estimate by 0.2% [1][9] Financial Performance - The growth in revenue was driven by higher net revenue per discharge, which rose 4.1% year over year, and an increase in total discharges, which grew 5.3% year over year to 67,238, although this figure marginally missed the consensus estimate by 0.3% [2][5] - Total operating expenses increased by 7.5% year over year to $1.26 billion, primarily due to rising salaries and benefits, but this was slightly below the estimated $1.28 billion [6][9] - Net income for the quarter climbed 23.7% year over year to $203.1 million, while adjusted EBITDA grew 15.9% year over year to $335.6 million, surpassing the estimate of $304 million [6][9] Operational Developments - In the fourth quarter, Encompass Health added 37 beds to its existing hospitals and opened three de novo hospitals [7][9] - For the full year 2025, the company reported operating revenues of $5.94 billion, up from $5.37 billion in 2024, with adjusted net income per share increasing to $5.45 from $4.43 [13] Future Outlook - For 2026, net operating revenues are projected to be between $6.365 billion and $6.465 billion, indicating growth from the 2025 figure [14] - Adjusted EBITDA is expected to range from $1.34 billion to $1.38 billion, reflecting an increase from the 2025 figure [14] - The company anticipates adjusted EPS from continuing operations to be between $5.81 and $6.10, up from $5.45 in 2025 [15] - Encompass Health plans to open eight de novo hospitals and add approximately 175 beds to existing facilities in 2026 [16] Growth Strategy - Management aims to inaugurate six to ten de novo hospitals each year from 2023 to 2027, with a target of adding 80-120 beds annually and achieving a compound annual growth rate (CAGR) of 6-8% in discharges during the same period [17]

Core Insights - National Research Corporation (NRC) shares have declined 27.2% since the earnings report for Q4 2025, significantly underperforming the S&P 500 index's 1.1% decline during the same period [1] - The company reported adjusted earnings per share of 16 cents for Q4 2025, down from 29 cents in the prior-year period [1] Financial Performance - Total revenues for Q4 2025 were $35.2 million, reflecting a 5% decline compared to the prior-year quarter [2] - GAAP net income for Q4 was $1.8 million, a sharp decrease from $6.6 million a year earlier, while adjusted net income was $3.4 million, down from $6.7 million [2] - For the full year 2025, revenues declined 4% year-over-year to $137.4 million, attributed to elevated client attrition in H2 2024 [3] - Adjusted EPS for the full year fell to 93 cents from $1.05, and adjusted net income decreased 17% to $20.7 million [3] - Adjusted EBITDA for Q4 was $8.7 million, representing 25% of revenues [4] Cash Flow and Recurring Revenue - Cash flow from operations for Q4 increased 13% year-over-year to $7.2 million, accounting for 20% of revenue [5] - Full-year operating cash flow reached $26.5 million, down from $34.6 million in 2024, but still representing 19% of total revenue [5] - The company's recurring revenue remained high, with 99% of total revenue classified as recurring, indicating strong visibility into future earnings [5] Key Business Metrics - Total Recurring Contract Value (TRCV) increased 8% year-over-year to $144.1 million, marking the fifth consecutive quarter of sequential growth [6] - Management emphasized the importance of sales team realignment, product enhancements, and customer success initiatives in driving TRCV growth [6] Management Commentary - CEO Trent Green and CFO Shane Harrison acknowledged the challenges posed by elevated TRCV attrition in Q4 2024 but expressed optimism about momentum entering 2026 [7] - Green highlighted an 86% increase in new sales year-over-year and strong retention as positive outcomes of a refined go-to-market strategy [7] - Cost discipline was noted as a factor in preserving margins despite revenue pressure, allowing for continued investment in growth initiatives [7] Strategic Focus - The company emphasized a three-pronged customer value proposition: trust, expertise, and portfolio breadth, with a Net Promoter Score of 68 and 74% penetration among the top 100 U.S. health systems [8] - NRC is exploring strategic, accretive acquisitions and new growth avenues, including technology enhancements and partnerships through "Blue Water" opportunities [12] Future Outlook - Management expressed confidence in resuming revenue growth in 2026, supported by the 8% TRCV expansion in Q4 [11] - The evolving go-to-market model was described as a "meaningful tailwind" for the upcoming year [11]

Core Viewpoint - Auna SA is identified as a promising investment opportunity, particularly as analysts project significant upside potential due to its growth strategies and market positioning [1][2]. Group 1: Company Overview - Auna SA operates a vertically integrated network of healthcare facilities, including hospitals, clinics, and outpatient services across Peru, Colombia, and Mexico, with a focus on high-complexity care, especially in oncology and prepaid health plans [4]. - The company is currently trading at a low valuation of 4.5 times its estimated adjusted earnings for 2026, indicating potential for significant price appreciation [1]. Group 2: Growth Drivers - Auna's growth is expected to accelerate due to the expansion of its operations in Mexico, supported by a $500 million investment from Sojitz and the Trecca PPP project in Peru [2][3]. - The healthcare spending increase in Latin America is anticipated to benefit Auna, with strong growth reported in Peru and Colombia, which helped mitigate declines in Mexico [3]. Group 3: Market Context - The Latin American healthcare market is characterized by low penetration of private insurance, covering only about 10% of the population, presenting a substantial growth opportunity for Auna [2].